FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2345908908> ?p ?o ?g. }

• W2345908908 endingPage "e2818" @default.
• W2345908908 startingPage "e2818" @default.
• W2345908908 abstract "Background Both sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors can be used to treat patients with type 2 diabetes mellitus (T2DM) that is inadequately controlled with insulin therapy, and yet there has been no direct comparison of these two inhibitors. Methods We searched MEDLINE, EMBASE, LILACS, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov through June 2015. Randomized controlled trials published in English that compare SGLT2 inhibitor plus insulin (SGLT2i/INS) with placebo plus insulin or DPP4 inhibitor plus insulin (DPP4i/INS) with placebo plus insulin in patients with T2DM were selected. Data on the study characteristics, efficacy and safety outcomes were extracted. We compared the efficacy and safety between SGLT2i/INS and DPP4i/INS indirectly with covariates adjustment. Risk of potential bias was assessed. Results Fourteen eligible randomized controlled trials comprising 6980 patients were included (five SGLT2 inhibitor studies and nine DPP4 inhibitor studies). Covariate-adjusted indirect comparison using meta-regression analyses revealed that SGLT2i/INS achieved greater reduction in HbA1c [weighted mean difference (WMD) −0.24%, 95% confidence interval (CI) −0.43 to −0.05%], fasting plasma glucose (WMD −18.0 mg/dL, 95% CI −28.5 to −7.6 mg/dL) and body weight (WMD −2.38 kg, 95% CI −3.18 to −1.58 kg) from baseline than DPP4i/INS without increasing the risk of hypoglycaemia (relative risks 1.19, 95% CI 0.78 to 1.82). Conclusions Sodium glucose cotransporter 2 inhibitors achieved better glycaemic control and greater weight reduction than DPP4 inhibitors without increasing the risk of hypoglycaemia in patients with T2DM that is inadequately controlled with insulin. There has been no direct comparison of SGLT2 inhibitors and DPP4 inhibitors in patients with T2DM inadequately controlled with insulin therapy. In this study, we performed indirect meta-analysis comparing SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy. Without increasing hypoglycaemia, SGLT2 inhibitors showed better glycaemic control and greater weight reduction than DPP4 inhibitors in patients with T2DM inadequately controlled with insulin. The results of the current study could serve as the best available evidence in selecting oral agents to improve glycaemic control in insulin-treated T2DM patients. Copyright © 2016 John Wiley & Sons, Ltd." @default.
• W2345908908 created "2016-06-24" @default.
• W2345908908 creator A5017857826 @default.
• W2345908908 creator A5083812471 @default.
• W2345908908 creator A5090460555 @default.
• W2345908908 creator A5090737086 @default.
• W2345908908 date "2016-06-08" @default.
• W2345908908 modified "2023-10-14" @default.
• W2345908908 title "Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis" @default.
• W2345908908 cites W1847388060 @default.
• W2345908908 cites W1970406523 @default.
• W2345908908 cites W1977595596 @default.
• W2345908908 cites W2005368757 @default.
• W2345908908 cites W2009999012 @default.
• W2345908908 cites W2012932483 @default.
• W2345908908 cites W2017508478 @default.
• W2345908908 cites W2023623030 @default.
• W2345908908 cites W2035613798 @default.
• W2345908908 cites W2037857580 @default.
• W2345908908 cites W2038953694 @default.
• W2345908908 cites W2059245135 @default.
• W2345908908 cites W2059431020 @default.
• W2345908908 cites W2072040765 @default.
• W2345908908 cites W2081510795 @default.
• W2345908908 cites W2099326967 @default.
• W2345908908 cites W2101344933 @default.
• W2345908908 cites W2105660444 @default.
• W2345908908 cites W2109077746 @default.
• W2345908908 cites W2109688740 @default.
• W2345908908 cites W2118701488 @default.
• W2345908908 cites W2121242002 @default.
• W2345908908 cites W2122643907 @default.
• W2345908908 cites W2127833912 @default.
• W2345908908 cites W2141800817 @default.
• W2345908908 cites W2142418958 @default.
• W2345908908 cites W2144193100 @default.
• W2345908908 cites W2151345870 @default.
• W2345908908 cites W2157405334 @default.
• W2345908908 cites W2159205789 @default.
• W2345908908 cites W2160088494 @default.
• W2345908908 cites W2166613497 @default.
• W2345908908 doi "https://doi.org/10.1002/dmrr.2818" @default.
• W2345908908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27155214" @default.
• W2345908908 hasPublicationYear "2016" @default.
• W2345908908 type Work @default.
• W2345908908 sameAs 2345908908 @default.
• W2345908908 citedByCount "46" @default.
• W2345908908 countsByYear W23459089082017 @default.
• W2345908908 countsByYear W23459089082018 @default.
• W2345908908 countsByYear W23459089082019 @default.
• W2345908908 countsByYear W23459089082020 @default.
• W2345908908 countsByYear W23459089082021 @default.
• W2345908908 countsByYear W23459089082022 @default.
• W2345908908 countsByYear W23459089082023 @default.
• W2345908908 crossrefType "journal-article" @default.
• W2345908908 hasAuthorship W2345908908A5017857826 @default.
• W2345908908 hasAuthorship W2345908908A5083812471 @default.
• W2345908908 hasAuthorship W2345908908A5090460555 @default.
• W2345908908 hasAuthorship W2345908908A5090737086 @default.
• W2345908908 hasBestOaLocation W23459089081 @default.
• W2345908908 hasConcept C126322002 @default.
• W2345908908 hasConcept C134018914 @default.
• W2345908908 hasConcept C142724271 @default.
• W2345908908 hasConcept C156490143 @default.
• W2345908908 hasConcept C168563851 @default.
• W2345908908 hasConcept C204787440 @default.
• W2345908908 hasConcept C27081682 @default.
• W2345908908 hasConcept C2777180221 @default.
• W2345908908 hasConcept C2778763485 @default.
• W2345908908 hasConcept C2779306644 @default.
• W2345908908 hasConcept C2910068830 @default.
• W2345908908 hasConcept C44249647 @default.
• W2345908908 hasConcept C555293320 @default.
• W2345908908 hasConcept C71924100 @default.
• W2345908908 hasConcept C82789193 @default.
• W2345908908 hasConcept C90924648 @default.
• W2345908908 hasConcept C95190672 @default.
• W2345908908 hasConceptScore W2345908908C126322002 @default.
• W2345908908 hasConceptScore W2345908908C134018914 @default.
• W2345908908 hasConceptScore W2345908908C142724271 @default.
• W2345908908 hasConceptScore W2345908908C156490143 @default.
• W2345908908 hasConceptScore W2345908908C168563851 @default.
• W2345908908 hasConceptScore W2345908908C204787440 @default.
• W2345908908 hasConceptScore W2345908908C27081682 @default.
• W2345908908 hasConceptScore W2345908908C2777180221 @default.
• W2345908908 hasConceptScore W2345908908C2778763485 @default.
• W2345908908 hasConceptScore W2345908908C2779306644 @default.
• W2345908908 hasConceptScore W2345908908C2910068830 @default.
• W2345908908 hasConceptScore W2345908908C44249647 @default.
• W2345908908 hasConceptScore W2345908908C555293320 @default.
• W2345908908 hasConceptScore W2345908908C71924100 @default.
• W2345908908 hasConceptScore W2345908908C82789193 @default.
• W2345908908 hasConceptScore W2345908908C90924648 @default.
• W2345908908 hasConceptScore W2345908908C95190672 @default.
• W2345908908 hasIssue "1" @default.
• W2345908908 hasLocation W23459089081 @default.
• W2345908908 hasLocation W23459089082 @default.
• W2345908908 hasOpenAccess W2345908908 @default.

• next